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Abstract
Purpose: Vitamin B12 (cyanocobalamin, Cbl) is accumulated by rapidly replicating prokaryotic and
eukaryotic cells. We investigated the potential of a Tc-99m labelled Cbl derivative ([99mTc]PAMA(4)-
Cbl) for targeting infections caused by Escherichia coli and Staphylococcus aureus. In vitro binding
assays were followed by biodistribution studies in a mouse model of foreign body infection.
Procedures: E. coli (ATCC 25922) andS. aureus (ATCC43335)were usedas test strains. [57Co]Cbl,
[67Ga]citrate and [99mTc]DTPA served as reference compounds. The in vitro competitive binding of
[57Co]Cbl or [99mTc]PAMA(4)-Cbl, and unlabeled Cbl, to viable or killed bacteria, was evaluated at 37
and 4 °C. A cage mouse model of infection was used for biodistribution of intravenous [57Co]Cbl and
[99mTc]PAMA(4)-Cbl in cage and dissected tissues of infected and non-infected mice.
Results: Maximum binding (mean±SD) of [57Co]Cbl to viable E. coliwas 81.7±2.6 % and to S. aureus
34.0±6.7 %, at 37 °C; no binding occurred to heat-killed bacteria. Binding to both test strains was
displaced by 100- to 1000-fold excess of unlabeledCbl. The in vitro binding of [99mTc]PAMA(4)-Cbl was
100-fold and 3-fold lower than the one of [57Co]Cbl for E. coli and S. aureus, respectively. In vivo,
[99mTc]PAMA(4)-Cbl showed peak percentage of injected dose (% ID) values between 1.33 and 2.3, at
30 min post-injection (p.i.). Significantly higher retention occurred in cage fluids infected with S. aureus
at 4 h andwithE. coli at 8 h p.i. than in non-infected animals. Accumulation into infected cageswas also
higher than the one of [99mTc]DTPA, which showed similar biodistribution in infected and sterile mice.
[57Co]Cbl gradually accumulated in cageswith peaks% ID between 3.58 and 4.83%achieved from 24
to 48 h. Discrimination for infection occurred only inE. coli-infectedmice, at 72 h p.i. [67Ga]citrate, which
showed a gradual accumulation into cage fluids during 12 h, was discriminative for infection from 48 to
72 h p.i. (PG0.05).
Conclusion: Cbl displayed rapid and specific in vitro binding to test strains. [99mTc]PAMA(4)-Cbl
was rapidly cleared from most tissues and discriminated between sterile and infected cages,
being a promising candidate for imaging infections in humans.
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Introduction
B acterial infections are an important cause of morbidityand mortality worldwide. The accurate diagnosis of
infection (or its exclusion) is the first crucial step in the
management of these patients. Imaging techniques constitute
a non-invasive and attractive approach that, in the last
decades, has gained on importance by combining visualiza-
tion of radiopharmaceuticals and morphological imaging,
with positron emission tomography/X-ray computed tomog-
raphy (CT) and single photon emission computed
tomography/CT imaging [1, 2]. In various types of infec-
tions, including prosthetic joint infections, radionuclide
imaging techniques become essential when the diagnosis
remains unclear [3]. The current standard method is based
on labelling white blood cells isolated from patients [4–7].
Other agents have been developed in the past decade, such
as radiolabeled antimicrobials (ciprofloxacin, sparfloxacin,
ceftizoxime, isoniazid, ethambutol, fluconazole), antimicro-
bial peptides (29–31 UBI, human beta-defensin-3), cyto-
kines (IL-8), 2-deoxy-2-[18F]fluoro-D-glucose, growth
factors and bacteriophages [2, 8–15]. However, in pre-
clinical and clinical studies, these agents showed limitations,
in particular insufficient specificity for diagnosis infection,
making them unsuitable in the clinical practice [1, 16, 17].
Vitamin B12 or cobalamin (Cbl) is an important hydrophilic
enzyme cofactor required in fast replicating cells, such as bacteria
or fungi. In bacteria, Cbl catalyses transmethylation and rearrange-
ment reactions by binding to Cbl-dependent enzyme isoforms,
directly or indirectly responsible for the synthesis of ATP, amino
acids and nucleotides [18]. Comparative genomic analysis
revealed a wide distribution of genetic elements involved in the
regulation or uptake of Cbl derivatives [18]. Cbl transport systems
were studiedmainly in enteric bacteria. Especially, theEscherichia
coli Cbl uptake is mediated by an external membrane transporter
(BtuB, TonB-dependent), which transfer Cbl to a periplasmatic
protein (BtuF) and finally across the inner membrane (BtuCD,
ABC ATP-dependent) [19–21]. Gram-positive bacteria, as Staph-
ylococcus aureus, do not have an outer membrane, and thus
completely lack the BtuB carrier. However, element analogues to
the E. coli BtuCD inner membrane transporter were reported in
S. aureus and Staphylococcus epidermidis strains, and described as
less specific carriers of Cbl, and closely related molecules as heme
and siderophores [18]. The latter findings supported previous
in vitro studies of [57Co]Cbl uptake mechanism, which reported
high avidity of binding to several pathogen bacteria in different
culture conditions [22, 23].
The distinctive uptake mechanism in bacterial and animal
cells may represent the basis for development of radio-
labeled Cbl derivatives for specific targeting of bacterial
infections and for reduced systemic accumulation in vivo.
Cbl distributes through the blood circulation upon binding to
the transport protein transcobalamin II (TC II). The Cbl-TC
II complex is rapidly internalized through binding to the
transcobalamin II receptor (RTC II) and megalin receptor,
mainly expressed in humans in the kidneys, liver, intestine
lumen, glands and absorptive epithelia [24, 25]. A second
family of proteins, transcobalamin I (TC I or haptocorrins, or
R-type Cbl binders), binds free Cbl and cobinamides in the
blood. The TC I protein family was mainly found in
secondary granules of granulocytes and in salivary glands,
and its release has a protective function of reducing
pathogen colonization and growth [26, 27].
A [57Co]Cbl oral formulation was initially developed and
used in humans for diagnosis of vitamin B12 malabsorption
syndromes [28]. A similar intravenous formulation showed
potential targeting of tumour cells [29]. However, the long
half-life of the isotope [57Co]Cbl, together with its systemic
non-specific accumulation and persistence in several organs,
limited the maximal injectable dose to 1 μCi. This dose limit
prohibits the use of [57Co]Cbl for imaging purposes.
Therefore, vitamin B12 analogues were synthesized and
labelled with isotopes such as In-111 and Tc-99m. An In-
111 labelled Cbl derivative, diethylenetriamine-pentaacetate
adenosylcobalamin ([111In]DAC), showed promising results
for the diagnosis of various malignancies. Interestingly, in
the same study, [111In]DAC derivative accumulated in the
right wrist of one patient, who was diagnosed a staphylo-
coccal septic arthritis [30]. However, the high unspecific
accumulation of the [111In]DAC in non-target tissues made
this radiopharmaceutical inappropriate for routine clinical
application.
The Cbl derivative [99mTc]PAMA(4)-Cbl has been
recently developed and tested for imaging of malignancies
(Fig. 1) [31, 32]. This conjugate carries mono-anionic
ligands with a NNO donor set and can be efficiently labelled
with [[99mTc](OH2)3(CO)3]
+ at yields 995 % under mild
conditions (50 °C, 60 min) [31]. Importantly, [99mTc]PAMA
(4)-Cbl has abolished binding to the major Cbl transport
protein TC II. As a consequence, significantly lower uptake
in non-targeted tissue and organs was demonstrated in mice
bearing different tumour types.
In this study, we evaluated the potential of [99mTc]
PAMA(4)-Cbl for specific targeting E. coli and S. aureus
in vitro and in a cage model of foreign body infection in
mice (Fig. 2) [33]. The results were compared with the
TC II binding molecule [57Co]Cbl. The infection model
of subcutaneously implanted cages has been used in mice
for investigating pathophysiology and treatment efficacy
of implant-associated infection [34–36]. The kinetics and
histology of the infected cage closely resemble a human
infection of prosthesis with bacteria adherent to the
foreign body, infiltration of granulocytes and pus. The
model allows the induction of a localized persistent
infection, characterized by a high and reproducible
bacterial density of 107–109 colony forming units
(CFU) per millilitre of cage fluid. Cages fill with
inflammatory fluid (exudate) surrounded by a highly
vascularized tissue. We performed biodistribution studies
with [99mTc]DTPA to evaluate the local vascularization
of infected and non-infected cages. In addition, we tested
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the performance of [67Ga]citrate, an agent accumulating
unspecifically at sites of aseptic inflammation and




synthesized and labelled as described elsewhere [32]. Five
gigabecquerels of sodium [99mTc]pertechnetate was added to
the kit and heated for 20 min. The alkaline solution was
neutralized with a 1-M HCl solution and additionally buffered
with 1 M MES. This solution was added to 30 μg of the
lyophilized Cbl-b-(butyl)-PAMA-OEt. The reaction mixture was
kept at 75 °C for 75 min. The product was purified over a RP-
8 column (X-Terra RP8 5 μm 30×150 mm) using a gradient of
solvent A (10 % ethanol, 90 % 0.1 M acetate buffer) and B
(70 % ethanol/water). The collected fraction of about 1 ml was
diluted with phosphate buffer at pH 7.4 up to 10 ml. Aliquots
of the product were distributed according to the needs. Briefly,
DTPA (Pentacis®, IBA Molecular, Switzerland) was labelled in
10 ml of sterile 0.9 % saline with 3.05 GBq of sodium [99mTc]
pertechnetate, according to the manufacturer’s instructions, with
a labelling efficiency of 98.6 %. [57Co]cyanocobalamin ([57Co]
Cbl) 0.39 MBq/50 ng/ml was purchased by MP Biomedicals
(Diagnostic Division, Orangeburg, NY, USA). Gallium-67
citrate solution for injection was purchased at a radiochemical
concentration of 17.17 MBq/ml (Mallinckodt Schweiz AG,
Radiopharma, Wollerau, Switzerland).
Test Microorganisms
Laboratory strains E. coli (ATCC 25922) and S. aureus (ATCC
35556, methicillin susceptible) were used. Bacteria were stored at
−70 °C using a cryovial bead preservation system (Microbank, Pro-
Lab Diagnostics, Richmond Hill, ON, Canada). Single cryovial
Fig. 1. Chemical structure of [99mTc]PAMA4-Cbl.
Fig. 2. CT scan of a C57Bl/6 mouse with subcutaneous
implanted tissue cage, 2 weeks after surgery.
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beads were cultured overnight on Columbia sheep blood agar plates
(Becton Dickinson, Heidelberg, Germany).
For in vitro binding studies, overnight cultures were prepared in
snap-lid tubes from 2 to 3 CFU in 5 ml of a synthetic minimal
medium depleted of vitamin B12. After 18–20 h of incubation at
37 °C and 200 rpm, the cultures were diluted 1:100 in the same
medium and further incubated at 37 °C to mid-logarithmic phase in
sealed tubes.
For in vivo studies, overnight cultures were prepared in 5 ml
tryptic soy broth (TSB), incubated at 37 °C for 18–20 h. Bacterial
suspensions were then washed three times, resuspended in 5 ml of
sterile 0.9 % saline and diluted.
In Vitro Binding Studies
The in vitro binding and internalization profiles of [57Co]Cbl and
[99mTc]PAMA(4)-Cbl to E. coli and S. aureus were characterized.
Stock solutions of the radiotracers were prepared at a concentration
of 0.004 MBq/ml (0.350–0.700 ng/ml, 0.3–0.5 pmol/ml) for [57Co]
Cbl and ≈1 MBq/ml (≈0.5 ng/ml, ≈0.3 pmol/ml) for [99mTc]PAMA
(4)-Cbl in phosphate-buffered solution (PBS). In competition
studies, 10-fold dilutions between 3 and 0.003 μg/ml of unlabeled
Cbl (Sigma-Aldrich, Steinheim, Germany) were added to the stock
radiotracer solutions.
Bacterial cultures in the logarithmic phase at OD600 between 0.4
and 0.6 were centrifuged and resuspended in equal volume of
sterile PBS. Five hundred microlitres of resuspended cultures were
transferred to Eppendorf tubes and used for the measurement of
binding to viable bacteria at 37 °C. For testing binding at 4 °C,
bacterial suspension in PBS were let to equilibrate for 1 h at 4 °C
before adding the radiopharmaceuticals. In order to evaluate the
binding to killed bacteria, bacterial cultures were either exposed to
heat at 99 °C or to 70 % ethanol at 4 °C for 30 min (E. coli) or
60 min (S. aureus). The bacterial suspensions were then centri-
fuged, resuspended in PBS and used for further studies. The PBS
resuspended heat-killed or ethanol-killed bacteria were sampled on
Columbia blood agar plates, and the CFU were enumerated after
24 h of incubation at 37 °C. Colony counts remained G10 CFU/ml.
Five hundred microlitres of each radiopharmaceutical solution
was added to the 500 μl of bacterial suspensions. Binding assays
were performed in quadruplicate vials per testing conditions.
Afterwards, vials were centrifuged for 5 min at 13,500 rpm and
4 °C, and pellets were washed with 500 μl of cooled PBS.
Supernatants and resuspended pellets were counted in a multi-well
NaI γ-counter (Cobra; Packard, USA) and the counts per minute
(CPM) recorded. The percentage of radiolabeled Cbl in the pellets
was calculated as the percentage of the CPMp/CPM0 ratio per log10
8.0 CFU/ml, where CPMp were the CPM associated to pellets and
CPM0 were the total CPM of the radiolabeled Cbl added per vial.
In vitro binding of the radiotracers was measured after 5, 30, 60,
120 min (E. coli and S. aureus) and 180 min (S. aureus) of
incubation at 37 and 4 °C.
Competition binding studies were measured for cultures
incubated for 1 h (E. coli) and 3 h (S. aureus), at 37 and 4 °C,
simultaneously with 10-fold serial dilution of unlabeled Cbl and
either [57Co]Cbl or [99mTc]PAMA(4)-Cbl. In addition, competition
with unlabeled Cbl was studied on bacterial cultures previously
incubated with [57Co]Cbl or [99mTc]PAMA(4)-Cbl for 20 min
(E. coli) or 2 h (S. aureus) and further exposed to the unlabelled-
labelled Cbl mixtures for 10 min (E. coli) or 1 h (S. aureus).
Tissue Cage Infection Model in Mice
C57Bl/6 mice from in-house breeding or purchased from Charles
River Laboratories GmbH (Sulzfeld, Germany) were housed in the
Animal Facility of the Department of Biomedicine, University
Hospital, Basel, Switzerland. Experiments were performed in
accordance to the regulations of Swiss veterinary law. The
Institutional Animal Care and Use Committee approved the study
protocol. Drinking water and standard laboratory food pellets (CR)
were provided ad libitum. To reduce interference of high vitamin
B12 level in mice, animals randomized for Cbl biodistribution
studies were fed with a vitamin B12-reduced diet (Provimi Kliba
AG, Kaiseraugst, Switzerland) beginning at the age of 10 weeks. At
the age of 12 weeks, one sterile polytetrafluoroethylene (Teflon)
tube (32×10 mm), perforated by 130 regularly spaced holes of
1 mm diameter, was aseptically implanted into the back of each
mouse, as previously described [33, 36]. Each cage was weighted
and numbered before implantation. Two weeks after surgery, clips
were removed from healed wounds, and sterility of the cage was
confirmed by culture of aspirated cage fluid. On the following day,
5×105 CFU of E. coli or 5×106 CFU of S. aureus, resuspended in
200 μl of 0.9 % saline, were injected into cages. Sterile 0.9 %
saline was injected in cages in animals used as negative controls.
Biodistribution Studies
Biodistribution studies were performed in control and infected
mice, 24 h (for E. coli) or 48 h (for S. aureus) after infection. The
bacterial counts in cage fluid were enumerated by plating 10-fold
serial dilutions of cage fluid, after 24 h of incubation at 37 °C.
A hundred microlitres of isotonic saline solution containing
≈6 ng/3.3 pmol/10 MBq of [99mTc]PAMA(4)-Cbl and 0.25 mg/
≈10 MBq of [99mTc]DTPA was injected into the lateral tail vein of
each mouse, randomized for a minimum of nine mice per infection
group (E. coli, S. aureus or sterile mice) per radiopharmaceutical.
Distribution of radiopharmaceuticals into the cage fluids was
determined at 30 min, 1, 2, 4, 8, 12 and 24 h. Distribution into
organs, tissues and explanted cages was measured at 30 min, 4 and
24 h after injection.
One hundred microlitres of isotonic saline solution containing
1.2–2.3 ng/0.9–1.7 pmol /0.014 MBq [57Co]Cbl or 0.83 pg/
0.172 MBq of [67Ga]citrate was injected into the lateral tail vein
of each mouse, randomized for a minimum of four mice per
infection group (E. coli, S. aureus or control mice) per radiophar-
maceutical. Cage fluids were measured at 1, 6, 24, 48 and 72 h p.i.
Animals were euthanized at 72 h, and the total-body biodistribution
was determined.
The two different experimental set-up of biodistribution were
adapted to the known radiopharmaceutical binding/non-binding to
plasma protein, persistence in organs and tissues and half-life of the
labelling radioisotope.
Accumulation of radiopharmaceuticals in cage fluids was
measured by resuspending 100 μl of aspirated fluid in 1 ml PBS
and counted in a gamma counter. The percentage of injected dose
(% IDTCF/ml) was calculated as measured CPM normalized per
1 ml cage fluid and divided by the CPM0 (injected dose). For
determination of radiopharmaceutical biodistribution, mice were
sacrificed with an intraperitoneal injection of 50–80 μl saline
solution of pentothal (100 mg/ml). Blood was collected by cardiac
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puncture, and mice were perfused with 0.9 % saline for around
5 min. Following, tissues were dissected, weighted and collected
into test tubes for γ-counter (blood, heart, liver, spleen, stomach,
kidneys, lungs, intestine, muscle, bone and cage). The percentage
of injected dose (% IDtissue/g) was calculated as CPM associated to
each organ divided by its weight in grams and by the CPM0.
Statistical Analysis
Comparisons of in vitro binding results and in vivo biodistribution
data were performed using the Student’s t test for continuous
variables. All results were given as mean values±SEM, unless
otherwise indicated. P values of G0.05 were considered significant.
All calculations were performed using Prism 4.0a (GraphPad
Software, La Jolla, CA, USA).
Results
In Vitro Binding Studies
Binding of [57Co]Cbl to viable E. coli and S. aureus was
time dependent. E. coli showed a rapid binding with plateau
reached already 10 min after incubation in a temperature-
independent fashion (Fig. 3a). With S. aureus, [57Co]Cbl
displayed a slower binding kinetic and no plateau was
reached even after 3 h of incubation (Fig. 3b). In contrast to
E. coli, binding of S. aureus was temperature dependent
(approximately 3-fold higher at 37 than at 4 °C). The
maximum binding (mean±SD) was measured at 37 °C and
was 81.7±2.6 % for E. coli and 34.0±6.7 % for S. aureus.
Binding of [57Co]Cbl to ethanol-killed E. coli was lower
than the one observed in viable bacteria, while no binding
was measured with heat-killed E. coli, whereas 5[57Co]Cbl
did not show any binding to both ethanol-killed and heat-
killed S. aureus.
Binding of [99mTc]PAMA(4)-Cbl to E. coli was low, non-
displaceable and ranged between 0.1 and 0.3 % in all the
tested conditions (living bacteria as well as ethanol- and
heat-killed bacteria, data not shown). When testing the
S. aureus strain, the binding of [99mTc]PAMA(4)-Cbl to
viable bacteria at 37 °C and 3 h of incubation was 11.43±
1.7 %, and, similarly to the one obtained with the [57Co]Cbl,
it was slow and temperature dependent, with no binding to
killed bacteria (Fig. 3c).
[57Co]Cbl could be displaced by non-radioactive Cbl in a
concentration-dependent manner. A 1000-fold concentration
of unlabeled Cbl was required to show an inhibition of
binding to E. coli at 37, while at 4 °C and in ethanol-killed
bacteria, a 10-fold cold Cbl excess was sufficient to reduce
the maximal binding to 50 % (Fig. 4a). The S. aureus
binding to [57Co]Cbl was reduced already by 10-fold excess
of unlabeled Cbl at both 37 and 4 °C (Fig. 4b). Already 1-
fold of unlabeled Cbl decreased the binding of [99mTc]
PAMA(4)-Cbl to S. aureus (Fig. 4c). At 37 °C, the binding
of [57Co]Cbl to E. coli achieved after 20 min of incubation
was unchanged upon the following addition of the unlabeled
Cbl. Differently, at 4 °C, the binding showed a slight
decrease when challenged with 1000-fold excess of unla-
beled Cbl. Binding of [57Co]Cbl to ethanol-killed E. coli
could be reversed by the excess of cold, independently on
the pre-incubation with the labelled Cbl (Fig. 5a). Similar
mechanisms were also observed when S. aureus was pre-
exposed to [57Co]Cbl or [99mTc]PAMA(4)-Cbl: the mea-
sured binding was only slightly reduced upon later challenge
with excess of unlabeled vitamin, both at 37 and 4 °C
(Fig. 5b, c).
Biodistribution Studies
On the day of radiopharmaceutical injection, the mean±
SD bacterial counts were 9.4±0.82 log10 CFU/ml for
E. coli and 6.3±0.62 log10 CFU/ml for S. aureus. Three
days after radiopharmaceutical injection ([57Co]Cbl and
[67Ga]citrate biodistribution studies), bacterial counts
were 8.6±0.2 log10 CFU/ml for E. coli and 7.8±0.1
Fig. 3. Kinetic of in vitro binding (mean CPM/CPM0%±SD) of [
57Co]Cbl to aE. coli and bS. aureus at different incubation times.
Kinetic of in vitro binding (mean CPM/CPM0%±SD) of [
99mTc]PAMA(4)-Cbl to cS. aureus at different incubation times. At 37 °C
(closed circles, continuous line), 4 °C (open circles, dashed line), ethanol-killed bacteria (closed triangles, dotted line) and heat-
killed bacteria (closed diamonds, dashed-dotted line). Note that X- and Y-axes are scaled depending on the bacterium or
radiopharmaceutical tested.
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log10 CFU/ml for S. aureus. Spontaneous cure was not
observed in any infected cage. No clinical or patholog-
ical signs of systemic infection were observed during
organ dissection. The highest concentration of [99mTc]
PAMA(4)-Cbl was measured in sterile cage fluids at
early time points (Fig. 6a). The maximum [99mTc]PAMA
(4)-Cbl % IDTCF/ml at 30 min was 2.3±0.39 % for
sterile cages, 1.33±0.26 % for infected cages with
E. coli and 2.06±0.79 % for infected cages with
S. aureus. Clearance from sterile cages was faster in
infected cages, and the % IDTCF/ml was significantly
lower in controls than in infected mice with S. aureus at
4 h (P=0.042) and with E. coli at 8 h (P=0.0035).
[99mTc]PAMA(4)-Cbl cage fluid/blood ratios discriminat-
ed between non-infected mice (1.53±0.30) and infected
mice, both with S. aureus (13.48±2.75, P=0.0036) or
E. coli (6.31±2.92, PG0.0001), at 24 h p.i. Indeed, the
radiopharmaceutical was rapidly cleared from blood,
whereas retention of radioactivity was observed in the
kidneys up to 24 h after injection. In explanted cages,
the radiopharmaceutical retention did not significantly
differ in infected and sterile conditions up to 4 h, but it
was discriminative at 24 h for E. coli-infected cages (P=
0.0375), with % ID/g nearly 10-fold higher than in
sterile cages (Table 1).
[99mTc]DTPA was used in vivo to evaluate the vascular-
ization of sterile and infected cage fluids. The radiopharma-
ceutical showed an early peak in cage fluids and cage
tissues, ranging between 1.5 and 3 %. Following, clearance
was fast from all, sterile and infected cages and tissues
(Fig. 6b).
The distribution profile of [57Co]Cbl is shown in Fig. 6c.
[57Co]Cbl displayed a continuous penetration into cage
fluids, with peaks achieved between 24 and 48 h in sterile
and S. aureus-infected cages. A plateau % IDTCF/ml of
[57Co]Cbl into E. coli-infected cages was not achieved up to
72 h. Clearance from cage fluids was also slow and was
similar in sterile and S. aureus-infected mice. Only cages
infected with E. coli at 72 h showed significantly higher
radiopharmaceutical retention in the cage fluid, when
compared to control mice (P=0.0032). The cage fluid/
blood ratios at 72 h in control mice (1.40±0.19) were
slightly discriminative for infected cages with E. coli (1.72±
0.07, P=0.04), but not with S. aureus (1.52±0.10, P90.05).
Fig. 4. In vitro displacement of binding of [57Co]Cbl to viable and non-viable aE. coli and to bS. aureus; in vitro displacement of
binding of [99mTc]PAMA(4)-Cbl to cS. aureus; viable bacteria at 37 °C (empty bar) or 4 °C (filled bar) and non-viable bacteria
after ethanol fixation (diagonal hatched bars, E. coli only). Significant differences between binding in the absence and in the
presence of cold Cbl (at different concentrations) are indicated as follows: *PG0.05, **PG0.005, ***PG0.0005. Note that X- and
Y-axes are scaled depending on the bacterium or radiopharmaceutical tested.
Fig. 5. In vitro displacement of binding by non-labelled Cbl added after pre-incubation of a [57Co]Cbl and E. coli, b [57Co]Cbl
and S. aureus and c of [99mTc]PAMA(4)-Cbl and S. aureus. Viable bacteria at 37 °C (empty bar), at 4 °C (filled bar) and non-
viable bacteria after ethanol fixation (diagonal hatched, E. coli only). Significant differences between binding in the absence and
in the presence of cold Cbl (at different concentrations) are indicated as follows: *PG0.05, **PG0.005, ***PG0.0005. Note that X-
and Y-axes are scaled depending on the bacterium or radiopharmaceutical tested.
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At 72 h, [57Co]Cbl remained in high percentage in the blood,
liver and kidneys.
Similarly to [57Co]Cbl, [67Ga]citrate penetration into cages
was gradual, and peak values were achieved within 12 h.
Clearance was faster in sterile compared to infected cages and
tissues (Fig. 6d). The [67Ga]citrate retention in cage fluid
became significantly higher in infected than in non-infected
animals at 48 h (P=0.029) and 72 h (P=0.0006). At 72 h,
accumulation became also significantly higher in explanted
cages of infected mice with both S. aureus (PG0.0001) and
E. coli (P=0.0019). The cage fluid/blood ratio at 72 h of [67Ga]
citrate in non-infected animals was 1.14±0.21, which was
lower than in mice infected with E. coli (5.41±0.52,
PG0.0001) or S. aureus (3.56±0.87, P=0.0003). The distribu-
tion in tissues and organs at 72 h after injection showed the
highest Ga-67 uptake into the liver, kidneys and bone, while
the radiopharmaceutical was mostly cleared from the remain-
ing tissues.
Fig. 6. Distribution of a [99mTc]PAMA(4)-Cbl, b [99mTc]DTPA, c [57Co]Cbl and d [67Ga]citrate into tissue cage fluids of sterile
(dotted line), S. aureus-infected (dashed line) and E. coli-infected (continuous line) cages. Data represent % ID/ml of tissue fluid,
expressed as means±1 SEM of three to five different mice.
Table 1. Organ and tissue distribution after i.v. injection of [99mTc]PAMA(4)-Cbl, [99mTc]DTPA, [57Co]Cbl and [67Ga]citrate in sterile, E. coli and S. aureus
tissue cage infected mice
Organ or tissue [99mTc]PAMA(4)-Cbl [99mTc]DTPA [57Co]vitamin B12 [
67Ga]citrate
30 min 4 h 24 h 30 min 4 h 24 h 72 h 72 h
Blood 1.79±0.05 0.15±0.02 0.02±0.10 1.46±1.10 0.02±0.10 0.01±0.00 2.55±0.35 0.46±0.20
Heart 0.90±0.07 0.33±0.07 0.11±0.01 0.15±1.10 0.05±0.00 0.01±0.00 3.60±0.68 1.26±0.10
Liver 5.75±0.86 2.98±0.45 0.92±0.90 0.33±0.20 0.09±0.00 0.02±0.00 15.78±1.49 7.44±0.90
Stomach 1.73±0.30 0.49±0.23 0.44±0.14 1.67±1.70 0.05±1.10 0.02±0.00 4.83±0.85 3.73±1.50
Spleen 1.48±0.18 0.60±0.07 0.22±0.03 0.19±0.00 0.06±0.00 0.02±0.00 9.07±1.44 6.09±0.70
Kidneys 15.66±1.88 13.47±1.79 11.19±1.35 3.92±0.80 0.93±0.80 0.15±0.00 25.91±4.64 10.73±1.30
Lungs 2.81±0.51 1.09±0.26 0.29±0.10 0.40±0.20 0.06±0.10 0.01±0.00 3.72±1.75 2.11±0.30
Intestine 1.81±0.14 1.52±0.51 0.59±0.05 0.90±0.50 0.66±0.20 0.02±0.00 3.63±0.89 2.00±0.40
Bone 0.74±0.05 0.22±0.01 0.08±0.01 0.47±0.30 0.05±1.50 0.01±0.00 3.93±0.96 10.99±2.40
Muscle 0.38±0.03 0.09±0.01 0.03±0.01 0.34±0.30 0.06±1.10 0.00±0.00 1.42±0.20 0.69±0.20
Cage—sterile 2.37±0.16* 0.87±0.25 0.04±0.01#* 2.88±0.50 0.34±0.40* 0.01±0.00 4.60±0.41* 1.45±0.50#*
Cage—S. aureus 1.80±0.91 1.47±0.38 0.14±0.06 n.d. 0.40±0.10 0.05±0.10 4.88±0.55 9.45±2.30
Cage—E. coli 0.76±0.21 0.84±0.23 0.37±0.18 n.d. 0.91±0.15 0.15±0.10 6.52±0.17 3.99±1.10
Values are expressed as mean % ID/g tissue±SD
n.d. not determined
#PG0.04 and 0.004 vs S. aureus; *PG0.005 or 0.03 or 0.003 or 0.001 or 0.02 vs E. coli
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Discussion
In vitro studies demonstrated that the bacterial binding of
[57Co]Cbl is specific and displaceable by excess of unla-
belled Cbl. Higher binding avidity was measured for the
E. coli, rather than the S. aureus strain. When E. coli and
S. aureus cultures were pre-exposed to [57Co]Cbl, only
small fractions of the bound agent could be displaced by
unlabeled Cbl, indicating fast internalization. In agreement
with an energy-dependent uptake mechanism, the internal-
ized fractions were higher at 37 than at 4 °C, and they were
exclusively measured in viable bacteria.
The in vitro binding of [99mTc]PAMA(4)-Cbl derivative to
E. coli was significantly lower for [57Co]Cbl. Indeed, the
technetium chelator of [99mTc]PAMA(4)-Cbl is linked to the b-
acid of the corrin ring A, a functional group involved in hydrogen
bonds with the amine groups of Leucin and Alanin residues in the
BtuB binding pocket, theE. coli outer membrane transporter [18].
In contrast, binding of [99mTc]PAMA(4)-Cbl to S. aureus was
specific, and only slightly lower than [57Co]Cbl. The S. aureus
receptor mediating Cbl uptake is evidently less affected by Cbl
modifications than the E. coli outer membrane transporter BtuB.
In animal studies, [99mTc]PAMA(4)-Cbl showed a fast
penetration into all cages, followed by a slower release in
infected cages than in sterile ones. The retention of this
radiopharmaceutical into infected fluids became significantly
higher at 4 h p.i. for S. aureus-infected mice and at 8 h p.i.
for E. coli-infected mice, which is in accordance with a
lower receptor affinity of PAMA(4)-Cbl for E. coli BtuB
receptors. The uptake measured in cage fluid of infected
animals was also significantly higher for [99mTc]PAMA(4)-
Cbl than for the non-specific radiopharmaceutical [99mTc]
DTPA. This finding supports a specific interaction of
[99mTc]PAMA(4)-Cbl with the colonizing bacteria, rather
than a non-specific retention due to the morphological
differences between infected and sterile cage fluids.
Differently, [57Co]Cbl and by [67Ga]citrate had a slow
kinetic of penetration into both infected and sterile cages,
explained by their high plasma protein binding and long
persistence in blood and organs [37, 38]. [57Co]Cbl was only
partially cleared from sterile cages even after 72 h p.i.
Significantly higher retention in sterile mice could be
observed in cages infected with E. coli at 72 h. The latter
result is in accordance to the higher [57Co]Cbl binding
measured in vitro to E. coli than to S. aureus.
The mechanism of the [67Ga]citrate accumulation at
infection/inflammation site is associated to the Ga (III)
binding to transferrin, lactoferrin and other inflammatory
proteins in inflamed sites, internalization into the cells with
active metabolic pathway as citrate for citric acid cycle and
presumable binding to bacterial siderophores [37, 39]. In
our studies, [67Ga]citrate discriminated between infected
and sterile cages from 48 h after injection. The retention of
the radiopharmaceutical observed in the bone, kidneys,
liver and spleen is in accordance with data from previous
publications [40].
In our cage infection studies, radiopharmaceutical accu-
mulation was several times higher in the cage fluid than in
the tissue surrounding explanted cages. While explanted
cages contain residues of clotted tissue and cage-adherent
bacteria in a stationary growth phase, the cage fluid
represents the active infection site with replicating bacteria
in the planktonic growth phase [33]. Consequently, in the
tissue cage mouse model of infection, cage fluids, rather
than explanted cages, may represent a better sample for
evaluation of radiopharmaceuticals targeting infection.
Conclusions
In our study, the tissue cage mice model of infection demon-
strated to be a valid alternative to other experimental models for
screening radiotracers targeting infection, such as osteomyelitis,
infectious endocarditis and infection of thigh muscles [41]. The
model has the advantages that infection profiles are highly
reproducible planktonic bacterial number is easy to measure, as
well as radiotracers kinetic at the site of infection. Indeed, cage
fluids can be sampled several times during the experiment,
thereby avoiding sacrificing animals for each time point.
Furthermore, we showed that radiolabeled Cbl has a specific
receptor-mediated binding to E. coli and S. aureus. In vivo, the
[99mTc]PAMA(4)-Cbl derivative discriminated between infected
and non-infected cages in the mouse model within 4 to 8 h after
radiopharmaceutical injection, and thus may become a selective
radiopharmaceutical for targeting infections in humans.
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